Precision Wormlike Nanoadjuvant Governs Potency of Vaccination.
It remains unclear how the precise length of one-dimensional nanovehicles influences the characters of vaccination. Here, a unimolecular nanovehicle with tailored size and aspect ratio (AR) is applied to deliver CpG oligodeoxynucleotide, a Toll-like receptor (TLR) 9 agonist, as an adjuvant of recombinant hepatitis B virus surface antigen (rHBsAg), for treating chronic hepatitis B (CHB). Cationic nanovehicles with fixed width (ca. 45 nm) but varied length (46 nm-180 nm), AR from 1 to 4, are prepared through controlled polymerization and are loaded with CpG by electrostatic interaction. We reveal that the nanoadjuvant with AR = 2 shows the highest retention in proximal lymph nodes. Importantly, it is more easily internalized into antigen-presenting cells and accumulates in the late endosome, where TLR9 is located. Such a nanoadjuvant exhibits the strongest immune response with rHBsAg to clear the hepatitis B virus in the CHB mouse model, showing that the AR of nanovehicles governs the efficiency of vaccination.
['Sun|Ziyang|Z|', 'Qiao|Dongdong|D|', 'Shi|Yi|Y|0000-0003-2943-5465', 'Barz|Matthias|M|0000-0002-1749-9034', 'Liu|Lixin|L|0000-0001-6133-4977', 'Chen|Yongming|Y|0000-0003-2843-5543']
D000276:Adjuvants, Immunologic D000818:Animals D004195:Disease Models, Animal D051379:Mice D014611:Vaccination
Nanoadjuvant Chronic hepatitis B Lymph node targeting Molecular bottlebrush Nanovaccine